In a long-term extension study, belimumab proved safe, demonstrating low organ damage accrual in SLE patients treated for up to nine years…
FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis
The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…
Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
NEW YORK (Reuters Health)—Romosozumab improves bone mineral density (BMD) in men with osteoporosis, but safety concerns are holding up its approval in the U.S. Up to 2 million men in the U.S. have osteoporosis, and up to 13 million have osteopenia, researchers note in a report online June 20 in The Journal of Clinical Endocrinology…
IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval
In its first phase 3 clinical trial, intravenous tramadol has met its primary endpoint for relieving postoperative pain…
FDA Approves Baricitinib for RA Patients
The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…
Disease-Modifying Antirheumatic Drugs Cut RA Risk
NEW YORK (Reuters Health)—Disease-modifying antirheumatic drugs (DMARDs) reduce the risk of developing rheumatoid arthritis (RA) in patients with early undifferentiated arthritis, researchers from France report. Several studies have suggested that conventional or biological DMARDs might interfere with the pathogenic process and prevent more established forms of RA, but it remains unclear whether these drugs are…
Study Results for 9 New Psoriatic Arthritis Drugs
CHICAGO—As Eric Ruderman, MD, professor of medicine in rheumatology at Northwestern University Feinberg School of Medicine in Chicago, began his talk on psoriatic arthritis treatment at the ACR State-of-the-Art Clinical Symposium in April, he marveled a bit at how much there was to cover. Drugs gaining prominence in the treatment of rheumatoid arthritis and dermatological…
When Is It Appropriate to Discontinue Bisphosphonates?
CHICAGO—A 75-year-old woman with low bone density, who has had a fracture and has other risk factors for fracture, is treated with the bisphosphonate alendronate. After five years on the drug she comes back, wondering: Should I stop taking the drug? She’s had no additional fractures. Her bone density has improved, but her lumbar spine…
Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App
CHICAGO—As good an option as hydroxychloroquine (HCQ) is for many patients with rheumatic diseases, such as rheumatoid arthritis and especially lupus, safety must be an important consideration, an expert said at this April’s ACR State-of-the-Art Clinical Symposium. The use of the antimalarial has become a controversial subject, with clinicians trying to balance the drug’s disease-modifying…
Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 122
- Next Page »